

# PROthrombin complex concentrate versus fresh frozen Plasma for bleeding in adults undergoing HEart SurgerY (PROPHECY-2 trial)

<b>Submission date</b> 25/01/2024	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 16/04/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 19/01/2026	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Every year in the UK, severe bleeding occurs in over 10,000 people having cardiac surgery. Severe bleeding increases the risks of complications like organ failure and infections, or death. Stopping bleeding quickly could reduce these risks and improve outcomes. Currently, severe bleeding is stopped by transfusion of fresh frozen plasma (FFP), part of donated blood that contains essential proteins for blood clotting. This study aims to determine whether a blood product called prothrombin complex concentrate (PCC) is a superior treatment to a blood product called FFP for adult patients who are actively bleeding within 24 hours of cardiac surgery.

### Who can participate?

Patients aged 18 years and over who are actively bleeding within 24 hours of cardiac surgery

### What does the study involve?

Potentially eligible patients will be consented and screened before their cardiac surgery, and if they go on to develop bleeding during or within 24 hours of surgery, they will be randomised to receive either PCC or FFP. Participants will be followed up for 90 days (+/- 7 days) post-surgery and will complete a series of questionnaires relating to their general health, the specific disease that caused them to undergo heart surgery, and the healthcare costs associated with their recovery

### What are the possible benefits and risks of participating?

There is no increased risk for patients in this research: the blood product has been used widely in the UK and Europe to treat bleeding in patients with no major safety concerns. If the patient haemorrhages during or soon after surgery, they will require a transfusion regardless so there is no additional treatment required in this trial. There is a small risk that patients may feel uncomfortable being treated with a product that they are not familiar with, in which case they should decline participation in the research. There is a potential burden with completing questionnaires, but research staff can complete these with the patients to decrease that burden. Some participants may have concerns about their data being used for research. The participant

information sheets clearly outline who is responsible for maintaining the integrity and confidentiality of the data, and who they can contact if they have questions.

Where is the study run from?

Queen Mary University of London (UK)

When is the study starting and how long is it expected to run for?

January 2024 to September 2026

Who is funding the study?

National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?

Charlie Brown, [Prophesy2Trial@nhsbt.nhs.uk](mailto:Prophesy2Trial@nhsbt.nhs.uk)

## Contact information

### Type(s)

Public

### Contact name

Mr Charlie Brown

### Contact details

Oxford Blood Centre

John Radcliffe Hospital

Oxford

United Kingdom

OX3 9BQ

+44 (0)20 7823351963 ext 0

[Prophesy2Trial@nhsbt.nhs.uk](mailto:Prophesy2Trial@nhsbt.nhs.uk)

### Type(s)

Scientific, Principal investigator

### Contact name

Dr Laura Green

### Contact details

4 Newark St

London

United Kingdom

E1 2AS

+44 (0)7720275360

[laura.green@qmul.ac.uk](mailto:laura.green@qmul.ac.uk)

## Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

## **Integrated Research Application System (IRAS)**

1009308

## **ClinicalTrials.gov (NCT)**

Nil known

## **Protocol serial number**

IRAS 1009308

# **Study information**

## **Scientific Title**

PROthrombin complex concentrate versus fresh frozen Plasma for bleeding in adults undergoing HEart SurgerY (PROPHEsy-2 trial): a phase III, randomised control trial

## **Acronym**

PROPHEsy-2

## **Study objectives**

Primary objective:

To find out whether prothrombin complex concentrate (PCC) is better at treating bleeding within 24 hours of cardiac surgery than the current standard care, fresh frozen plasma (FFP). Both are blood products that are widely used in the UK and Europe.

Secondary objective:

To determine if PCC is a better product than FFP when looking at the bigger picture, including organ failure, death, recovery from surgery, stay in hospital (including in intensive care and need for intubation), general health and safety outcomes.

## **Ethics approval required**

Ethics approval required

## **Ethics approval(s)**

approved 15/04/2024, London Fulham REC (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8084; fulham.rec@hra.nhs.uk), ref: 24/LO/0133

## **Study design**

Randomized controlled pragmatic non-blinded multi-site trial

## **Primary study design**

Interventional

## **Study type(s)**

Efficacy, Safety

## **Health condition(s) or problem(s) studied**

Haemorrhage within 24 hours of the start of cardiac surgery

## **Interventions**

Cardiac surgery patients who haemorrhage during or within 24 hours of the start of surgery are randomly allocated to receive either the current standard treatment (fresh frozen plasma, FFP, or LG Octaplas), or the IMP, Prothrombin Complex Concentrate (PCC).

FFP and LG Octaplas are plasma products and are the current recommended products for the treatment of severe bleeding in patients undergoing cardiac surgery.

PCC dosage is calculated according to the patient's weight following the current national guidelines.

Both FFP/LG Octaplas and PCC are administered by injection.

Once the clinical decision has been made that a patient requires a blood transfusion during or within 24 hours of the start of cardiac surgery, the transfusion lab will be instructed to perform the randomisation via Sealed Envelope. The issued product is then administered to the patient. Patients in the IMP arm will receive a maximum of two doses of PCC. If continued treatment is required, any further doses will be FFP or LG Octaplas, according to the hospital's policy.

## **Intervention Type**

Drug

## **Phase**

Phase III

## **Drug/device/biological/vaccine name(s)**

Prothrombin Complex Concentrate [Human coagulation factor II, Human coagulation factor VII, Human coagulation factor IX, Human coagulation factor X, Protein C, Protein S]

## **Primary outcome(s)**

A composite of any of the following new events from 24 hours post-surgery up to 90 days post-surgery:

1. All-cause mortality according to clinical diagnosis
2. Acute respiratory failure according to clinical diagnosis
3. Acute myocardial injury according to clinical diagnosis
4. Acute renal failure requiring renal replacement therapy (excluding dialysis during cardiopulmonary bypass) according to clinical diagnosis
5. Acute liver injury according to clinical diagnosis
6. Acute intestinal injury according to clinical diagnosis
7. Focal neurological deficit according to clinical diagnosis
8. Infection according to clinical diagnosis

## **Key secondary outcome(s)**

1. Individual components of the primary outcome up to 90 days or death, whichever occurs first:
  - 1.1. All-cause mortality according to clinical diagnosis
  - 1.2. Acute respiratory failure according to clinical diagnosis
  - 1.3. Acute myocardial injury according to clinical diagnosis
  - 1.4. Acute renal failure requiring renal replacement therapy (excluding dialysis during cardiopulmonary bypass) according to clinical diagnosis
  - 1.5. Acute liver injury according to clinical diagnosis
  - 1.6. Acute intestinal injury according to clinical diagnosis
  - 1.7. Focal neurological deficit according to clinical diagnosis
  - 1.8. Infection according to clinical diagnosis
2. Clinical evidence of haemostasis defined as:
  - 2.1. Amount of blood loss (in ml) collected in chest drains at 6 hours and 24 hours post end of

surgery, taken from clinical notes

2.2. Amount of total allogeneic (in units) blood transfusion (red blood cells, fresh frozen plasma, cryoprecipitate, platelets), total dose of haemostatic factor concentrates (PCC, fibrinogen concentrate, activated recombinant factor VIIa, or any other blood product concentrate) at 24 hours and 7 days from randomisation, taken from clinical notes

2.3. Whether re-exploration for bleeding up to 7 days post end of surgery was required, and whether a surgical point of bleeding was identified, taken from clinical notes

3. Length of stay in hospital, measured in days, up to and including 90 days from randomisation or hospital discharge or death whichever occurs first – i.e. time to discharge from acute care after index hospitalisation; this includes time to discharge from satellite acute care units; taken from clinical notes

4. Duration of mechanical ventilation (in days) during index hospitalisation up to 90 days from randomisation or hospital discharge or death, whichever occurs first, taken from clinical notes

5. Number of hospital re-admissions up to and including 90 days from randomisation, taken from medical records

6. Safety measured through:

6.1. Transfusion adverse events up to 7 days or hospital discharge or death, whichever is first, taken from clinical notes.

These will be defined as per UK Serious Hazard of transfusion (<https://www.shotuk.org/reporting>) definitions and will include:

6.1.1. Acute transfusion reactions, that could result in shock or cardiac arrest, taken from clinical notes

6.1.2. Haemolytic transfusion reactions (acute or delayed), taken from clinical notes

6.1.3. Post-transfusion purpura, taken from clinical notes

6.1.4. Transfusion-associated graft versus host disease, taken from clinical notes

6.1.5. Transfusion-associated circulatory overload, taken from clinical notes

6.1.6. Transfusion-associated dyspnoea, taken from clinical notes

6.1.7. Transfusion-related acute lung injury, taken from clinical notes

6.2. Thrombotic events (arterial and venous) confirmed by radiological imaging, autopsy, or through surgical means, up to 90 days or death, whichever occurs first, taken from clinical notes

6.3. Other serious adverse events reported up to 90 days or death whichever occurs first, taken from clinical notes

7. Quality of Life (QoL) measured using the:

7.1. EQ-5D-5L at baseline, 42 days and 90 days after randomisation

7.2. Disease-specific QoL questionnaire, either:

7.2.1. Coronary Revascularization Outcome (CROQ) at baseline and 90 days after randomisation for CABG, or

7.2.2. Kansas City Cardiomyopathy (KCCQ) at baseline and 90 days after randomisation for valve surgery

Both meet the minimum metric properties and have been previously validated in coronary bypass surgery

8. In-patient hospital costs, and separately follow-up health care costs at 90 days as provided in questionnaire responses and according to patient records

Measured at varying time points from 24 hours post-surgery to 90 days post-surgery

**Completion date**

31/05/2027

## Eligibility

**Key inclusion criteria**

1. Age  $\geq 18$  years
2. Undergoing cardiac surgery (Elective and Urgent procedures) not described in the exclusion criteria

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

100 years

**Sex**

All

**Total final enrolment**

0

**Key exclusion criteria**

1. Emergency and Salvage procedures (as per definitions in section 6.0)
2. First-time isolated coronary artery bypass graft (CABG) surgery given the low risk of significant bleeding
3. First time isolated aortic valve replacement (excluding active endocarditis)
4. First time isolated mitral valve replacement
5. Surgeries that do not involve cardiopulmonary bypass
6. Heart transplant
7. Use of warfarin within 3 days prior to surgery
8. Use of direct oral anticoagulants (i.e. dabigatran, rivaroxban, apixaban or edoxaban etc) within 48 hours prior to surgery (or 72 hours if patient has renal impairment – i.e. estimated glomerular filtration rate of  $<30$  ml/min)
9. Any contraindication to PCC or FFP or LG-Octaplas, for example: known or suspected allergy to heparin, Sodium citrate dihydrate, sodium dihydrogenphosphate dihydrate and Glycine, History of Heparin-induced thrombocytopenia, history of blood transfusion reaction due to IgA deficiency with known antibodies against IgA
10. Patients refusing blood transfusion for any reason
11. Inherited bleeding disorder (i.e. any inherited clotting factor deficiencies, or platelet disorders)
12. Pregnancy as PCC is contraindicated
13. Documented thrombophilia defects (antiphospholipid syndrome, severe protein S deficiency, antithrombin deficiency)
14. Documented venous thromboembolism in the last 3 months prior to surgery

15. Patients who are expected to require Extracorporeal Membrane Oxygenation after cardiac surgery
16. Patient previously randomised into this trial and has not reached 90 days post randomisation

**Date of first enrolment**

06/02/2025

**Date of final enrolment**

31/05/2027

## **Locations**

**Countries of recruitment**

United Kingdom

England

Wales

**Study participating centre**

**St. Bartholomew's Hospital**

Barts Health NHS Trust, West Smithfield

London

England

EC1A 7BE

**Study participating centre**

**Castle Hill Hospital**

Castle Road

Cottingham

England

HU16 5JQ

**Study participating centre**

**Glenfield Hospital**

Groby Road

Leicester

England

LE3 9QP

**Study participating centre**

**Derriford Hospital**

Derriford Road

Derriford  
Plymouth  
England  
PL6 8DH

**Study participating centre**  
**Southampton General Hospital**  
Tremona Road  
Southampton  
England  
SO16 6YD

**Study participating centre**  
**Bristol Royal Infirmary**  
Marlborough Street  
Bristol  
England  
BS2 8HW

**Study participating centre**  
**New Cross Hospital**  
Wolverhampton Road, Heath Town  
Wolverhampton  
England  
WV10 0QP

**Study participating centre**  
**King's College Hospital**  
Denmark Hill  
London  
England  
SE5 9RS

**Study participating centre**  
**Hammersmith Hospital**  
Du Cane Road  
Hammersmith  
London  
England  
W12 0HS



**Study participating centre**  
**Royal Papworth Hospital**  
Papworth Road  
Cambridge Biomedical Campus  
Cambridge  
England  
CB2 0AY

**Study participating centre**  
**St Georges Hospital**  
Blackshaw Road  
Tooting  
London  
England  
SW17 0QT

**Study participating centre**  
**University Hospital of Wales**  
Heath Park  
Cardiff  
Wales  
CF14 4XW

## **Sponsor information**

**Organisation**  
Queen Mary University of London

**ROR**  
<https://ror.org/026zzn846>

## **Funder(s)**

**Funder type**  
Government

**Funder Name**  
National Institute for Health and Care Research

**Alternative Name(s)**

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

## Results and Publications

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Data sharing statement to be made available at a later date

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		17/01/2026	19/01/2026	Yes	No
<a href="#">Study website</a>		11/11/2025	11/11/2025	No	Yes